9 results on '"G. Batist"'
Search Results
2. PCN252 TIME-TO-TREATMENT INITIATION (TTI) IN COMMUNITY INFUSION CLINICS: DECREASING WAIT TIMES FOR CANADIAN ONCOLOGY PATIENTS
- Author
-
A. Drinkwater, S. Anderson, P. Nijjar, C. Chiasson, A. Pabla, S.V. Sethi, S. Ghedira, A. Khan, J. Hopkins, G. Batist, B. Yap, and H. Wehbi
- Subjects
medicine.medical_specialty ,business.industry ,Health Policy ,Emergency medicine ,Public Health, Environmental and Occupational Health ,Time to treatment ,Medicine ,Oncology patients ,business - Published
- 2020
- Full Text
- View/download PDF
3. Lectures
- Author
-
D. S. Chen, D. M. Feltquate, F. Smothers, A. Hoos, S. Langermann, S. Marshall, R. May, M. Fleming, F. S. Hodi, A. Senderowicz, K. G. Wiman, S. de Dosso, W. Fiedler, L. Gianni, S. Cresta, H. B. Schulze-Bergkamen, L. Gurrieri, M. Salzberg, B. Dietrich, A. Danielczyk, H. Baumeister, S. Goletz, C. Sessa, D. Strumberg, B. Schultheis, A. Santel, F. Gebhardt, W. Meyer-Sabellek, O. Keil, K. Giese, J. Kaufmann, M. Maio, G. Choy, A. Covre, G. Parisi, H. Nicolay, E. Fratta, E. Fonsatti, L. Sigalotti, S. Coral, P. Taverna, M. Azab, E. Deutsch, C. Lepechoux, J. P. Pignon, Y. T. Tao, S. Rivera, B. C. Bourgier, M. Angokai, R. Bahleda, K. Slimane, E. Angevin, B. B. Besse, J. C. Soria, K. Dragnev, J. H. Beumer, B. Anyang, T. Ma, F. Galimberti, C. P. Erkmen, W. Nugent, J. Rigas, K. Abraham, D. Johnstone, V. Memoli, E. Dmitrovsky, E. E. Voest, L. Siu, F. Janku, A. Tsimberidou, R. Kurzrock, J. Tabernero, J. Rodon, R. Berger, A. Onn, G. Batist, C. Bresson, V. Lazar, J. J. Molenaar, J. Koster, M. Ebus, D. A. Zwijnenburg, P. van Sluis, F. Lamers, L. Schild, I. van der Ploeg, H. N. Caron, R. Versteeg, J. Pouyssegur, I. Marchiq, J. Chiche, D. Roux, R. Le Floch, S. E. Critchlow, R. F. Wooster, S. Agresta, K. E. Yen, P. A. Janne, E. R. Plummer, G. Trinchieri, L. Ellis, S. L. Chan, W. Yeo, A. T. Chan, F. Mouliere, S. El Messaoudi, C. Gongora, P. J. Lamy, M. del Rio, E. Lopez-Crapez, B. Gillet, M. Mathonnet, D. Pezet, M. Ychou, A. R. Thierry, V. Ribrag, W. Vainchenker, S. Constantinescu, H. Keilhack, I. A. Umelo, A. Noeparast, G. Chen, M. Renard, C. Geers, J. Vansteenkiste, E. Teugels, J. de Greve, O. Rixe, X. Qi, Z. Chu, J. Celerier, L. Leconte, N. Minet, J. Pakradouni, B. Kaur, F. Cuttitta, A. J. Wagner, Y. X. Zhang, E. Sicinska, J. T. Czaplinski, S. P. Remillard, G. D. Demetri, S. Weng, L. Debussche, L. Agoni, E. P. Reddy, C. Guha, K. Silence, A. Thibault, H. de Haard, T. Dreier, P. Ulrichts, M. Moshir, S. Gabriels, J. Luo, C. Carter, A. Rajan, S. Khozin, A. Thomas, A. Lopez-Chavez, C. Brzezniak, L. Doyle, C. Keen, M. Manu, M. Raffeld, G. Giaccone, S. Lutzker, J. M. Melief, S. G. Eckhardt, L. Trusolino, G. Migliardi, E. R. Zanella, F. Cottino, F. Galimi, F. Sassi, S. Marsoni, P. M. Comoglio, A. Bertotti, M. Hidalgo, S. J. Weroha, P. Haluska, M. A. Becker, S. C. Harrington, K. M. Goodman, S. E. Gonzalez, M. al Hilli, K. A. Butler, K. R. Kalli, A. L. Oberg, I. J. Huijbers, R. Bin Ali, C. Pritchard, M. Cozijnsen, N. Proost, J. Y. Song, P. Krimpenfort, E. Michalak, J. Jonkers, A. Berns, U. Banerji, A. Stewart, P. Thavasu, S. Banerjee, and S. B. Kaye
- Subjects
Oncology ,Hematology - Published
- 2013
- Full Text
- View/download PDF
4. Lectures
- Author
-
J. Doroshow, E. T. Liu, M. Pellini, V. Miller, G. Palmer, S. Averbuch, G. Green, J. Novotny, P. Paoletti, K. Patel, A. Hoos, R. Gaynor, S. Melemed, C. Reinhard, B. T. Teh, W. K. Hong, E. Kim, R. Herbst, V. Papadimitrakopoulou, K. Gold, I. Wistuba, J. Lee, S. Lippman, J. R. Jackson, L. Zitvogel, C. Meisel, P. Workman, W. S. Dalton, N. Botwood, B. J. Davis, G. Batist, S. Assouline, E. Camlioglu, B. Tetu, A. Spatz, Z. Diaz, A. Aguilar-Mahecha, M. Basik, J. Rodon, R. Dienstmann, J. Cortes, C. Saura, C. Aura, J. Hernandez-Losa, A. Vivancos, J. Joan, J. del Campo, E. Felip, J. Seoane, J. T. Tabernero, S. H. Friend, A. M. Tsimberidou, D. S. Hong, J. J. Wheler, Y. Ye, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock, M. Naley, P. Johnson, K. Schuerer, M. Lopes, L. E. Hood, Y. Yarden, and J. Quackenbush
- Subjects
Oncology ,Hematology - Published
- 2012
- Full Text
- View/download PDF
5. Technology & tools development
- Author
-
E. Pefani, N. Panoskaltsis, A. Mantalaris, M. C. Georgiadis, E. N. Pistikopoulos, A. Aguilar-Mahecha, J. Lafleur, C. Seguin, M. Rosenbloom, E. Przybytkowski, M. Pelmus, Z. Diaz, G. Batist, M. Basik, J. Tavernier, L. Brunet, J. Bazot, M. Chemelle, C. Dalban, S. Guiu, C. di Martino, J. Lehtio, M. Branca, H. Johansson, M. Orre, V. Granholm, J. Forshed, M. Perez-Bercoff, L. Kall, K. V. Nielsen, L. Andresen, S. Muller, S. Matthiesen, A. Schonau, R. Oktriani, A. Wahyono, S. Haryono, A. Utomo, T. Aryandono, T. Gagnon-Kugler, C. Rousseau, T. Alcindor, R. Aloyz, S. Assouline, D. Bachvarov, L. Belanger, E. Camlioglu, M. Cartillone, B. Chabot, R. Christodoulopoulos, C. Courtemanche, A. Constantin, N. Benlimame, I. Dao, R. Dalfen, L. Gosselin, F. Habbab, M. Hains, T. Haliotis, T. H. Nielsen, M. Joncas, P. Kavan, R. Klink, A. Langlaben, M. Lebel, B. Lesperance, K. Mann, J. Masson, P. Metrakos, S. McNamara, W. H. Miller, M. Orain, L. Panasci, E. Paquet, M. Phillie, S. Qureshi, D. Rodrigue, A. Salman, A. Spatz, B. Tetu, A. Tosikyan, M. Tsatoumas, T. Vuong, R. Ruijtenbeek, R. Houtman, R. de Wijn, P. Boender, R. Hilhorst, Y. Cohen, A. Onn, A. Lax, A. Yosepovich, S. Litz, S. Kalish, R. Felemovicius, G. Hout-Silony, M. Gutman, M. Shabtai, D. Rosin, A. Valeanu, E. Winkler, M. Sklair-Levy, B. Kaufman, I. Barshack, V. Canu, A. Sacconi, F. Biagioni, F. Mori, A. di Benedetto, L. Lorenzon, S. di Agostino, A. Cambria, S. Germoni, G. Grasso, R. Blandino, V. Panebianco, V. Ziparo, O. Federici, P. Muti, S. Strano, F. Carboni, M. Mottolese, M. G. Diodoro, E. Pescarmona, A. Garofalo, G. Blandino, T. Ho, L. Feng, S. Lintula, K. A. Orpana, J. Stenman, S. El Messaoudi, F. Mouliere, M. del Rio, A. S. Guedj, C. Gongora, F. M. Molina, P. J. Lamy, E. Lopez-Crapez, F. Rolet, M. Mathonnet, M. Ychou, D. Pezet, A. R. Thierry, M. Manuarii, O. Tredan, T. Bachelot, G. Clapisson, A. Courtier, G. Parmentier, T. Rabeony, A. Grives, S. Perez, J. F. Mouret, D. Perol, S. Chabaud, I. Ray-Coquard, I. Labidi-Galy, P. Heudel, J. Y. Pierga, C. Caux, J. Y. Blay, N. Pasqual, and C. Menetrier-Caux
- Subjects
Engineering management ,Development (topology) ,Oncology ,business.industry ,Medicine ,Hematology ,business - Published
- 2012
- Full Text
- View/download PDF
6. Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancer
- Author
-
G. Batist
- Subjects
Oncology ,medicine.medical_specialty ,Cardiotoxicity ,Anthracycline ,business.industry ,medicine.medical_treatment ,General Medicine ,medicine.disease ,Metastatic breast cancer ,Breast cancer ,Therapeutic index ,Quality of life ,Internal medicine ,Medicine ,Surgery ,Doxorubicin ,business ,Adjuvant ,medicine.drug - Abstract
Summary Improving the therapeutic index of anthracycline-based regimens in the management of metastatic breast cancer is a goal that physicians strive for in orderto improve quality of life and increase the small fraction of long-term disease-free survivors that have been observed in studies using anthracycline-based regimens. There are supporters and opponents of continuous and dose-intensive therapy for improving quality of life and providing a survival advantage, but the risk of cumulative toxicity associated with anthracycline-based regimens, especially, doxorubicin, is limiting in these approaches. Myocet™, has equivalent antitumour efficacy to doxorubicin, but significantly less cardiotoxicity. Consequently, the recommended cumulative lifetime dose of Myocet is 780 mg/m 2 , compared with 450 mg/m 2 for doxorubicin. By using Myocet in the metastatic setting, and perhaps eventually in the adjuvant treatment for primary breast cancer, an increased number of cycles can be givenwithin the cardiotoxicity risk threshold, improving quality of life by delaying relapse. This improvement in therapeutic index may contribute to the fraction of long-term disease-free survivors and fulfils a previously unmet need in the overall management of breast cancer.
- Published
- 2001
- Full Text
- View/download PDF
7. Synthesis and cytotoxic evaluation of some styryl ketones and related compounds
- Author
-
E. De Clercq, G. Batist, G. Y. Kao, Theresa M. Allen, Susan P.C. Cole, J. Yang, Jan Balzarini, Jonathan R. Dimmock, J. W. Quail, Mei-Hwa Chen, R. S. Reid, U. Pugazhenthi, and Praveen Kumar
- Subjects
Pharmacology ,chemistry.chemical_classification ,Ketone ,Chemistry ,Stereochemistry ,Aryl ,Organic Chemistry ,Biological activity ,General Medicine ,Mannich base ,Chemical synthesis ,Aldehyde ,Azine ,chemistry.chemical_compound ,Drug Discovery ,Isopropyl - Abstract
Summary A number of 1-aryl-4-methyl-1-penten-3-ones 1 were converted to the corresponding Mannich bases 2 and analogues 3 . Attempts to form the azines 4 from several members in series 1 led to the isolation of the corresponding pyrazolines 5 or aryl aldehyde azines 6 . Replacement of the isopropyl group of a compound in series 1 by methyl and ethyl functions led to ketones that reacted with hydrazine producing the corresponding azines. The Mannich bases displayed greater activity than the precursor ketones towards murine P388 and L1210 leukemia cells as well as to a panel of human tumour cell lines. Certain of the Mannich bases had selective toxicity towards some human tumour cell lines and others to L1210 cells (in contrast to human T lymphocytes). Several drug-resistant cell lines were shown to be free from cross resistance to a number of the Mannich bases.
- Published
- 1995
- Full Text
- View/download PDF
8. P.31 A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study
- Author
-
M.T.E. Puts, J. Monette, V. Girre, D. Wan-Chow-Wah, C. Pepe, L. Panasci, M. Basik, W.H. Miller, F. Retornaz, G. Batist, C. Wolfson, and H. Bergman
- Subjects
Oncology ,Hematology - Published
- 2007
- Full Text
- View/download PDF
9. The use of glycine as nitrogen source by Escherichia coli K12
- Author
-
S Isenberg, G Batist, P Weyman, E B Newman, V Kapoor, and J. Fraser
- Subjects
L-Serine Dehydratase ,Time Factors ,Nitrogen ,Auxotrophy ,Glycine ,Biophysics ,Biology ,medicine.disease_cause ,Cleavage (embryo) ,Biochemistry ,Serine ,Escherichia coli ,medicine ,Doubling time ,Amino Acids ,Molecular Biology ,Nitrogen cycle ,Glycine Hydroxymethyltransferase ,chemistry.chemical_classification ,Glycine cleavage system ,Enzyme ,chemistry ,Cell Division - Abstract
The use of glycine as nitrogen source by Escherichia coli K12 involves L-serine as obligatory intermediate. The pathway includes glycine cleavage enzymes, serine transhydroxymethylase and probably L-serine deaminase. This conversion of glycine to serine occurs in prototrophic strains only when glycine is used as nitrogen source. The growth rate with glycine as sole nitrogen source is slow; apparent doubling time 360 min.
- Published
- 1976
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.